Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Endothelin receptor antagonists.

Sophie Motte1, Kathleen McEntee, Robert Naeije

  • 1Laboratory of Physiology (CP-604), Free University Brussels, Erasmus Campus, Lennik Road 808, B-1070 Brussels, Edmonton, Canada.

Pharmacology & Therapeutics
|October 13, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The challenging combination of a high cardiac output and pulmonary arterial hypertension.

The European respiratory journal·2026
Same author

The cause of hypoxemia in pulmonary arteriovenous malformations.

American journal of respiratory and critical care medicine·2026
Same author

Haemodynamic diagnosis of pulmonary vascular disease in heart failure.

European heart journal·2026
Same author

Initial Combination of Macitentan With Riociguat in the Treatment of Pulmonary Arterial Hypertension.

Chest·2026
Same author

Prognostic Thresholds of Pulmonary Artery Pressure and Right Ventricular Function at Echocardiography in Heart Failure.

The American journal of cardiology·2026
Same author

Deep Learning Workflow In Echocardiography: John Henry's Saga Revisited?

Chest·2026

Endothelin receptor antagonists (ERAs) block endothelin-1's effects, showing promise for cardiovascular diseases. While effective for pulmonary arterial hypertension, their broader application requires further research.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Oncology

Background:

  • Endothelin-1 (ET-1) is a potent vasoconstrictor implicated in various cardiovascular and non-cardiovascular diseases.
  • ET-1 exerts its effects via endothelin receptor subtype A (ETA) and endothelin receptor subtype B (ETB) receptors.
  • Conditions associated with ET-1 include hypertension, heart failure, vascular remodeling, renal failure, cancer, and cerebrovascular disease.

Purpose of the Study:

  • To review the development and application of endothelin receptor antagonists (ERAs).
  • To discuss the efficacy of ERAs in various cardiovascular and non-cardiovascular conditions.
  • To explore the future potential of ERAs in disease treatment.

Main Methods:

  • Review of existing literature on endothelin receptor antagonists.

Related Experiment Videos

  • Analysis of clinical trial outcomes for ERAs in conditions like pulmonary hypertension and heart failure.
  • Examination of ongoing research into selective ETA and dual ETA/ETB antagonists.

    • Main Results:

    • Bosentan, a dual ETA/ETB antagonist, is approved for pulmonary arterial hypertension (PAH).
    • ERA trials in heart failure have yielded mixed results.
    • Ongoing studies investigate ERAs for lung fibrosis, cancer, and subarachnoid hemorrhage.

    Conclusions:

    • Non-peptidic ERAs with oral bioavailability are available.
    • Proven efficacy of ERAs is currently limited to pulmonary hypertension.
    • ERAs may hold future therapeutic potential for diverse cardiovascular and non-cardiovascular diseases.